Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer
March 4, 2025
Read More
Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within
Fierce Biotech: Merck & Co. signs $1.9B deal with Mestag to explore fibroblast therapies for inflammation